Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 570 of 5804
-
New drug combo aims to block cancer growth in RAS-Mutant tumors
Disease control OngoingThis phase II ComboMATCH treatment trial evaluates the effectiveness of palbociclib and binimetinib in treating patients with RAS-mutated cancers. Palbociclib and binimetinib are both in a class of medications called kinase inhibitors. They work by blocking the action of abnormal…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New prostate cancer trial aims to tailor treatment with Cutting-Edge imaging and DNA tests
Disease control Recruiting nowThis Investigator-initiated, Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers (THUNDER) study will be conducted in subjects with high-risk localized or locally advanced prostate cancer (PCa). The study contains both a randomized Phase…
Phase: PHASE2, PHASE3 • Sponsor: Cancer Research Antwerp • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Twice-Yearly shot could revolutionize HIV prevention for drug users
Prevention OngoingThe goals of this clinical study are to look at how lenacapavir (LEN) passes through the body and to assess the safety of LEN and emtricitabine/tenofovir disoproxil fumarate (F/TDF) for pre-exposure prophylaxis (PrEP) in people who inject drugs (PWID) in the United States (US). …
Phase: PHASE2 • Sponsor: Gilead Sciences • Aim: Prevention
Last updated Jun 27, 2026 09:10 UTC
-
New cocktail aims to stamp out stubborn ovarian cancer cells
Disease control Recruiting nowTo find out if combining pembrolizumab, bevacizumab (or an equivalent biosimilar drug), and low-dose cyclophosphamide can help control high-grade ovarian cancer that has MRD after treatment. The safety of this treatment combination will also be studied.
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New drug cocktail aims to tackle tough breast cancer
Disease control Recruiting nowThis phase II study is a clinical study to explore the efficacy and safety of SI-B003 monotherapy and BL-B01D1+SI-B003 combination therapy in patients with unresectable locally advanced or recurrent metastatic HER-2 negative breast cancer.
Phase: PHASE2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Poop pills may shield stem cell patients from deadly immune attack
Prevention OngoingThis randomized placebo-controlled double-blind phase II trial tests whether fecal microorganism (microbiota) transplantation prevents severe acute graft versus host disease in adults undergoing allogeneic hematopoietic cell transplantation (HCT). Fecal microbiota transplantation…
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Prevention
Last updated Jul 22, 2026 00:00 UTC
-
New drug duo aims to shrink enlarged spleens in myelofibrosis patients
Disease control Recruiting nowThis is an open, single-arm, multi-center clinical study designed to evaluate the efficacy and safety of TQ05105 Tablets combined with TQB3617 Capsules in patients with intermediate- and high-risk Myelofibrosis.
Phase: PHASE1, PHASE2 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
New hope for arthritis sufferers: experimental drug shows promise in Late-Stage trial
Disease control OngoingBrief Summary: This is a randomized, double-blind study comparing LNK01001 to placebo in Chinese participants with moderately to severely active rheumatoid arthritis who are on a stable dose of conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) and have an i…
Phase: PHASE3 • Sponsor: Lynk Pharmaceuticals Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New drug aims to help type 1 diabetes patients keep making insulin
Disease control OngoingThis is a randomized, parallel group, double-blind Phase 2 study with a blinded extension evaluating the safety and efficacy of 3 dose levels of frexalimab in comparison with placebo in participants with newly diagnosed T1D on insulin treatment. Study details include: Screening…
Phase: PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Lung cell therapy shows promise in IPF trial
Disease control CompletedIdiopathic pulmonary fibrosis (IPF) is a serious chronic (long term) disease with injury of lung tissues. REGEND001 is a cell therapy product, made from bronchial basal cells with ability to regenerate lung tissue, is promising to IPF treatment. This is a multi-center, randomized…
Phase: PHASE2 • Sponsor: Regend Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New drug shows promise in slowing lung scarring
Disease control OngoingThe study will evaluate the efficacy and safety of axatilimab in participants with IPF.
Phase: PHASE2 • Sponsor: Syndax Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New drug aims to let sunlight-sensitive patients enjoy the sun longer
Symptom relief CompletedTo investigate the efficacy of MT-7117 on time to onset and severity of first prodromal symptoms (burning, tingling, itching, or stinging) associated with sunlight exposure in adults and adolescents with EPP or XLP.
Phase: PHASE3 • Sponsor: Tanabe Pharma America, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 13:02 UTC
-
Nasal spray may offer quick fix for Children's racing heart
Disease control Recruiting nowNODE-202 is a Phase 2, multicenter, multinational, single dose, open-label, 2-part, sequential design study in pediatric patients with an established diagnosis of paroxysmal supraventricular tachycardia (PSVT) presenting with a symptomatic episode of PSVT. In Part 1, at least 30…
Phase: PHASE2 • Sponsor: Milestone Pharmaceuticals Inc. • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
New hope for kids with Crohn's: risankizumab trial launches
Disease control Recruiting nowCrohn's Disease (CD) is a gastrointestinal disease that can cause chronic diarrhea with or without gross bleeding, abdominal pain, weight loss, and fever. This study will assess the pharmacokinetics, efficacy, and safety of risankizumab in pediatric participants with moderately t…
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug combo aims to shrink advanced bladder tumors
Disease control Recruiting nowThis phase II study is designed to explore the efficacy and safety of SI-B003 monotherapy and BL-B01D1+SI-B003 combination therapy in patients with locally advanced or metastatic urothelial carcinoma and other solid tumors.
Phase: PHASE2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Could a meal kit delivery fight depression?
Disease control CompletedThis study experimentally investigates 1) whether ultra processed food (UPF) intake contributes to depression by increasing low mood and poor sleep due to blood glucose fluctuations (which then increases the desire to consume more UPFs) and 2) to investigate the effectiveness of …
Phase: NA • Sponsor: University of Michigan • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New drug cocktail aims to shrink Hard-to-Treat neuroendocrine tumors
Disease control Recruiting nowAn open-label, multicenter phase Ib/II clinical study to evaluate the safety and efficacy of LBL-024 combined with etoposide and platinum in the first-line treatment of patients with advanced neuroendocrine carcinoma (NEC)
Phase: PHASE1, PHASE2 • Sponsor: Nanjing Leads Biolabs Co.,Ltd • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Breakthrough stent aims to fix Hard-to-Treat aortic aneurysms
Disease control Recruiting nowThe Zenith® Fenestrated+ Endovascular Graft Clinical Study will assess the safety and effectiveness of the Zenith® Fenestrated+ Endovascular Graft (ZFEN+) in combination with the BeGraft Balloon-Expandable FEVAR Bridging Stent Graft System (BeGraft) and Unibody2 for the treatment…
Phase: NA • Sponsor: Cook Research Incorporated • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New shot during back surgery may boost spine healing in disc disease patients
Disease control TerminatedThe primary objective of the study is to assess the overall efficacy of a single intervertebral local administration of AGA111 in patients with degenerative disc disease undergoing lumbar interbody fusion.
Phase: PHASE3 • Sponsor: Angitia Biopharmaceuticals • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Lower drug dose after transplant may cut infections without losing protection
Disease control OngoingThe goal of this clinical trial is to determine the effectiveness of Reduced Dose Post-Transplant Cyclophosphamide (PTCy) in patients with hematologic malignancies after receiving an HLA-Mismatched Unrelated Donor (MMUD) . The main question\[s\] it aims to answer are: * Does a r…
Phase: PHASE2 • Sponsor: Center for International Blood and Marrow Transplant Research • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC